Full Press Release Details
Provides Business Update and First Quarter 2024 Financial Results
strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting date
Health completes MOU with The Ohio State's James Cancer Hospital
call and webcast to be held tomorrow, May 14th at 8:30 AM EDT
YORK, May 13, 2024 - PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified
commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided
a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health
Inc. ("Veris"), and presented financial results for the Company for the three months ended March 31, 2024.
webcast will take place on Tuesday, May 14, 2024, at 8:30 AM and is accessible in the investor relations section of the Company's
website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184
and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "PAVmed
Business Update" to join.
the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's
website at pavmed.com.
am very pleased with the strong progress PAVmed's subsidiaries have made on multiple fronts during the first quarter and recent
weeks," said Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer. "Lucid, PAVmed's strongest
and most advanced asset, is making great commercial progress and continues to successfully finance its operations through long-term fundamental
investors. Lucid now has the runway to advance through key reimbursement milestones on the pathway to profitability. As discussed last
quarter, we updated the PAVmed overall strategy to drive shareholder value through independently-financed subsidiaries that leverage
PAVmed's shared infrastructure. Veris and the PMX Incubator are progressing well in furtherance of this revised strategy."
from the first quarter and recent weeks include:
| Yesterday, Lucid reported that 1Q24 EsoGuard revenue was $1.0 million, which was flat compared to 4Q23 and represents a 124 percent increase from 1Q23. | |
| Strengthened balance sheet by Lucid's completion of a $29.8 million Series B Preferred Stock Offering . |
| Peer-reviewed publication of positive data from landmark National Cancer Institute (NCI)-sponsored clinical validation study, strengthening EsoGuard's clinical data supporting ongoing payor engagement. | |
| Secured July 17, 2024 MolDX pre-submission meeting to review data for technical assessment (TA) under its foundational Local Coverage Determination (LCD). | |
| Completed Memorandum of Understanding (MOU) with The Ohio State's James Cancer Hospital to implement pilot program enrolling their patients onto Veris Cancer Care Platform. | |
| Clear path to FDA clearance for Veris implantable monitor pending financing. | |
| Actively seeking to raise capital for PortIO Corp. as part of the PMX incubator initiative, which will also include other technologies such as EsoCure and CarpX. |
| For the three months ended March 31, 2024, EsoGuard related revenues were $1.0 million. Operating expenses were approximately $15.0 million which include stock-based compensation expenses of $1.9 million. GAAP net loss attributable to common stockholders was approximately $22.8 million, or $(2.62) per common share. | |
| As shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on the Company's financial results, the Company's non-GAAP adjusted loss was approximately $8.6 million or $(0.99) per common share. | |
| PAVmed had cash and cash equivalents of $25.5 million as of March 31, 2024, compared to $19.6 million as of December 31, 2023. | |
| The unaudited financial results for the three months ended March 31, 2024 were filed with the SEC on Form 10-Q on May 13, 2024, and are available at www.pavmed.com or www.sec.gov. |
| To supplement our financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company's financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA) and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense, loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, and loss on debt extinguishment. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP. | |
| Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures. | |
| Non-GAAP financial measures are provided to enhance readers' overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods. | |
| A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three months ended March 31, 2024 and 2023 are as follows: |
Consolidated Statement of Operations (Unaudited)
| For the three months ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| (in thousands except per-share amounts) | ||||||||
| Revenue | $ | 1,010 | $ | 446 | ||||
| Operating expenses | 15,046 | 20,847 | ||||||
| Other (Income) Expense | 4,476 | 1,813 | ||||||
| Net Loss | 18,512 | 22,214 | ||||||
| Net income (loss) per common share, basic and diluted | $ | (2.62 | ) | $ | (2.78 | ) | ||
| Net loss attributable to common stockholders | (22,788 | ) | (18,005 | ) | ||||
| Preferred Stock dividends and deemed dividends | 7,576 | 74 | ||||||
| Net income (loss) as reported | (15,212 | ) | (17,931 | ) | ||||
| Adjustments: | ||||||||
| Depreciation and amortization expense 1 | 586 | 727 | ||||||
| Interest expense (income), net 2 | (56 | ) | 62 | |||||
| NCI ownership share of Interest and Depreciation adjustments | (131 | ) | (168 | ) | ||||
| EBITDA | (14,813 | ) | (17,310 | ) | ||||
| Other non-cash or financing related expenses: | ||||||||
| Stock-based compensation expense 3 | 1,882 | 4,419 | ||||||
| ResearchDx acquisition/settlement paid in stock 1 | - | 713 | ||||||
| Change in FV convertible debt 2 | 2,163 | 1,040 | ||||||
| Offering costs convertible debt 2 | - | 1,186 | ||||||
| Loss on debt extinguishment 2 | 369 | 525 | ||||||
| Debt modification expense | 2,000 | - | ||||||
| Other non-cash charges | - | - | ||||||
| NCI ownership share of non-GAAP adjustments | (239 | ) | (1,742 | ) | ||||
| Non-GAAP adjusted (loss) | $ | (8,638 | ) | $ | (11,169 | ) | ||
| Basic and Diluted shares outstanding | 8,695 | 6,473 | ||||||
| Non-GAAP adjusted (loss) income per share | $ | (0.99 | ) | $ | (1.73 | ) |
Included in general and administrative expenses in the financial statements.
Included in other income and expenses.
Stock-based compensation ("SBC") expense included in operating expenses is detailed as follows in the table below by
category within operating expenses for the non-GAAP Net operating expenses:
of GAAP Operating Expenses to Non-GAAP Net Operating Expenses
| (in thousands except per-share amounts) | For the three months ended March 31, | |||||||
| 2024 | 2023 | |||||||
| Cost of revenue | $ | 1,744 | $ | 1,346 | ||||
| Stock-based compensation expense 3 | (36 | ) | (23 | ) | ||||
| Net cost of revenue | 1,708 | 1,323 | ||||||
| Amortization of acquired intangible assets | 372 | 505 | ||||||
| Sales and marketing | 4,311 | 4,539 | ||||||
| Stock-based compensation expense 3 | (403 | ) | (444 | ) | ||||
| Net sales and marketing | 3,908 | 4,095 | ||||||
| General and administrative | 6,678 | 10,407 | ||||||
| Depreciation expense | (214 | ) | (222 | ) | ||||
| ResearchDx acquisition/settlement paid in stock | - | (713 | ) | |||||
| Stock-based compensation expense 3 | (1,078 | ) | (3,588 | ) | ||||
| Net general and administrative | 5,386 | 5,884 | ||||||
| Research and development | 1,941 | 4,050 | ||||||
| Stock-based compensation expense 3 | (365 | ) | (364 | ) | ||||
| Net research and development | 1,576 | 3,686 | ||||||
| Total operating expenses | 15,046 | 20,847 | ||||||
| Depreciation and amortization expense | (586 | ) | (727 | ) | ||||
| ResearchDx acquisition/settlement paid in stock | - | (713 | ) | |||||
| Stock-based compensation expense 3 | (1,882 | ) | (4,419 | ) | ||||
| Net operating expenses | $ | 12,578 | $ | 14,988 |
PAVmed and its Subsidiaries
Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors.
Its majority-owned subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company
that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device-the
first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths.
Its other majority-owned subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through
remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external
devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port,
which will interface with the Veris Cancer Care Platform.
more and for more information about PAVmed, please visit pavmed.com.
more information about Lucid Diagnostics, please visit luciddx.com.
more information about Veris Health, please visit verishealth.com.
press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements
that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's
and Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking
statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's
and Lucid's common stock; PAVmed's Series Z warrants; general economic and market conditions; the uncertainties inherent
in research and development, including the cost and time required to advance PAVmed's and Lucid's products to regulatory
submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's and Lucid's clinical
and preclinical studies; whether and when PAVmed's and Lucid's products are cleared by regulatory authorities; market acceptance
of PAVmed's and Lucid's products once cleared and commercialized; PAVmed's and Lucid's ability to raise additional
funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult
to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's and
Lucid's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's and Lucid's most recent Annual
Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors"
in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention
or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions,
or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those
contained in the forward-looking statements.
PAVmed and Lucid Diagnostics